Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort
Open Access
- 8 March 2023
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (11) , 1313-1325
Abstract
Summary: Background and Aims: Phase III trials have established atezolizumab plus bevacizumab as the novel standard of care for patients with unresectable hepatocellular carcinoma (HCC). However, these trials raised concerns regarding treatment efficacy in non‐viral HCC, and it remains unclear whether combination immunotherapy is safe and effective in patients with advanced cirrhosis.Methods: One hundred patients with unresectable HCC initiated therapy with atezolizumab plus bevacizumab at our centre between January 2020 and March 2022. The control cohort consisted of 80 patients with advanced HCC who received either sorafenib (n = 43) or lenvatinib (n = 37) as systemic treatment.Results: Overall survival (OS) and progression‐free survival (PFS) were significantly longer within the atezolizumab/bevacizumab group and comparable to phase III data. The benefits in terms of increased objective response rate (ORR), OS and PFS were consistent across subgroups, including non‐viral HCC (58%). The ROC‐optimised neutrophil‐to‐lymphocyte ratio (NLR) cut‐off of 3.20 was the strongest independent predictor of ORR and PFS. In patients with advanced cirrhosis Child–Pugh B, liver function was significantly better preserved with immunotherapy. Patients with Child–Pugh B cirrhosis showed similar ORR but shorter OS and PFS compared to patients with preserved liver function.Conclusions: Atezolizumab plus bevacizumab showed good efficacy and safety in patients with unresectable HCC and partially advanced liver cirrhosis in a real‐world setting. Moreover, the NLR was able to predict response to atezolizumab/bevacizumab treatment and may guide patient selection.Keywords
This publication has 39 references indexed in Scilit:
- The immunology of hepatocellular carcinomaNature Immunology, 2018
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer, 2017
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON studyJournal of Hepatology, 2016
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupEuropean Journal of Cancer, 2016
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2014
- Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancerBritish Journal of Cancer, 2013
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnnals of Oncology, 2012
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Assessment of the prognosis of cirrhosis: Child–Pugh versus MELDJournal of Hepatology, 2005
- Natural History of Small Untreated Hepatocellular Carcinoma in Cirrhosis: A Multivariate Analysis of Prognostic Factors of Tumor Growth Rate and Patient SurvivalHepatology, 1992